Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandoz Group AGXSWX:SDZ -2.84%26 Intrinsic Value: Projected FCF is CHF0.00 as of Sep. 06, 2026. GuruFocus rates XSWX:SDZ with a GF Score™ of 26/100 and a GF Value™ of CHF46.98 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 635 Drug Manufacturers companies, Sandoz Group AG ranks worse than 157480.16% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-06), Sandoz Group AG's Intrinsic Value: Projected FCF is CHF0.00. The stock price of Sandoz Group AG is CHF68.36. Therefore, Sandoz Group AG's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.
The historical rank and industry rank for Sandoz Group AG's Intrinsic Value: Projected FCF or its related term are showing as below:
XSWX:SDZ's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.56 * Ranked among companies with meaningful Price-to-Projected-FCF only.
Sandoz Group AG (XSWX:SDZ) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Sandoz Group AG's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
68.36
/
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG Intrinsic Value: Projected FCF Related Terms
Sandoz Group AG Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG Intrinsic Value: Projected FCF Chart
XSWX:SDZ vs ZTS, UTHR, VTRS: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's Price-to-Projected-FCF falls into.
Sandoz Group AG Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
What does a Intrinsic Value: Projected FCF of CHF0.00 mean?
Sandoz Group AG (XSWX:SDZ) has a Intrinsic Value: Projected FCF of CHF0.00 as of Sep. 06, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Sandoz Group AG and its competitors. According to the industry distribution chart, Sandoz Group AG ranks #999999 out of 635 companies in the Drug Manufacturers industry.
Is Sandoz Group AG's Intrinsic Value: Projected FCF too high?
Sandoz Group AG's current Intrinsic Value: Projected FCF is CHF0.00. Based on the distribution chart, Sandoz Group AG ranks #999999 out of 635 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sandoz Group AG has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Intrinsic Value: Projected FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #999999 out of 635 companies for Intrinsic Value: Projected FCF. This places Sandoz Group AG in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.56, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current Intrinsic Value: Projected FCF is CHF0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Based on GuruFocus' analysis, Sandoz Group AG (XSWX:SDZ) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF46.98, compared to a current price of CHF68.36 — trading 45.5% above its estimated fair value. The current Intrinsic Value: Projected FCF is CHF0.00. Sandoz Group AG's overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current Intrinsic Value: Projected FCF is CHF0.00 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sandoz Group AG (XSWX:SDZ) Overvalued in 2026?
Based on GuruFocus' analysis, Sandoz Group AG stock appears to be overvalued.
The current stock price of CHF68.36 is trading 45.5% above its estimated GF Value™ of CHF46.98.
GuruFocus considers Sandoz Group AG to be Significantly Overvalued.
Key valuation signals for XSWX:SDZ:
Intrinsic Value: Projected FCF: CHF0.00
GF Value™: CHF46.98 vs. price of CHF68.36 (45.5% above fair value)
No single metric tells the full story. See the XSWX:SDZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
26GF Score
Get the complete analysis for XSWX:SDZ
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SDZ has been successfully added to your 
